Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.650
Open
2.570
VWAP
2.52
Vol
122.13K
Mkt Cap
68.06M
Low
2.480
Amount
307.85K
EV/EBITDA(TTM)
--
Total Shares
21.78M
EV
67.20M
EV/OCF(TTM)
--
P/S(TTM)
1.31
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Show More
2 Analyst Rating
Wall Street analysts forecast CELU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELU is 4.75 USD with a low forecast of 3.50 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.550
Low
3.50
Averages
4.75
High
6.00
Current: 2.550
Low
3.50
Averages
4.75
High
6.00
The End
No Data
Valuation Metrics
The current forward P/E ratio for Celularity Inc (CELU.O) is -0.61, compared to its 5-year average forward P/E of -3.40. For a more detailed relative valuation and DCF analysis to assess Celularity Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.40
Current PE
-0.61
Overvalued PE
0.56
Undervalued PE
-7.36
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.23
Current EV/EBITDA
-0.91
Overvalued EV/EBITDA
1.54
Undervalued EV/EBITDA
-5.99
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
20.61
Current PS
1.04
Overvalued PS
62.71
Undervalued PS
-21.49
Financials
Annual
Quarterly
FY2025Q2
YoY :
-52.64%
5.74M
Total Revenue
FY2025Q2
YoY :
+55.91%
-15.86M
Operating Profit
FY2025Q2
YoY :
-100.00%
N/A
Net Income after Tax
FY2025Q2
YoY :
+240.00%
-1.02
EPS - Diluted
FY2025Q2
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q2
YoY :
-152.05%
-40.97
Gross Profit Margin - %
FY2025Q2
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q2
YoY :
+698.21%
-427.60
Net Margin - %
FY2025Q2
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
1.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CELU News & Events
Events Timeline
2025-09-03 (ET)
2025-09-03
08:06:36
Celularity Meets Nasdaq Listing Requirements Again
2025-09-03
08:06:08
Celularity announces Q1 earnings per share of 84 cents, compared to a loss of $1.03 in the same period last year.
2025-08-22 (ET)
2025-08-22
17:31:10
Celularity issued a notice of noncompliance by Nasdaq
Sign Up For More Events
Sign Up For More Events
News
4.5
09-02BenzingaDow Drops More Than 1%; Nio Stock Declines Following Q2 Earnings Report
4.5
09-02BenzingaNasdaq Declines 1%; Signet Jewelers Reports Earnings Exceeding Expectations
4.0
08-18BenzingaWBB Securities Begins Coverage of Celularity with a Speculative Buy Rating and Sets Price Target at $6
Sign Up For More News
People Also Watch
FBIO
Fortress Biotech Inc
2.950
USD
-1.01%
BEDU
Bright Scholar Education Holdings Ltd
1.732
USD
+1.29%
NVNI
Nvni Group Ltd
0.581
USD
-2.02%
SSBI
Summit State Bank
11.875
USD
+0.30%
MDIA
Mediaco Holding Inc
1.340
USD
-0.74%
ARKR
Ark Restaurants Corp
6.850
USD
-1.42%
CLST
Catalyst Bancorp Inc
12.867
USD
-0.56%
OPI
Office Properties Income Trust
0.190
USD
-10.37%
KSCP
Knightscope Inc
5.650
USD
+1.07%
FAQ
What is Celularity Inc (CELU) stock price today?
The current price of CELU is 2.55 USD — it has increased 0 % in the last trading day.
What is Celularity Inc (CELU)'s business?
What is the price predicton of CELU Stock?
What is Celularity Inc (CELU)'s revenue for the last quarter?
What is Celularity Inc (CELU)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Celularity Inc (CELU)'s fundamentals?
How many employees does Celularity Inc (CELU). have?